Arena Pharmaceuticals, Inc. (ARNA) Financial Analysis & Valuation | Quarter Chart
Arena Pharmaceuticals, Inc. (ARNA)
ARNAPrice: $99.99
Fair Value: 🔒
🔒score
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Pha... more
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with ... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Amit Munshi |
| IPO Date | 2000-07-28 | CAGR | — |
| Employees | 448 | Website | www.arenapharm.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ARNA chart loading...
Fundamentals
Technicals
| Enterprise Value | $5.52B | P/E Ratio | -9.86 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 8.13 |
| P/CF Ratio | -12.11 | P/FCF Ratio | — |
| EPS | $-10.14 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -83.07% | Gross Margin | 1% |
| Operating Margin | -11338.41% | Profit Margin | -11492.44% |
| ROE | -0.71% | ROA | -0.79% |
| ROCE | -0.85% | Current Ratio | 8.59 |
| Quick Ratio | 8.59 | Cash Ratio | 3.39 |
| Debt/Equity | 0.06 | Interest Coverage | -147.22 |
| Altman Z Score | — | Piotroski Score | — |